Last quarter (Q4 2023), Prime Medicine, Inc.'s total revenue was $168.00K, an increase of Infinity% from the same quarter last year. In Q4, Prime Medicine, Inc.'s net income was $-26.25M. See Prime Medicine, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 168.00K	$ 168.00K	-	$ 0.00	$ 5.21M
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 168.00K	$ 168.00K	-	-	-
Operating Expense	$ 159.53M	$ 204.79M	$ -116.54M	$ 84.47M	$ 6.14M
Operating Income	$ -159.53M	$ -204.79M	$ -116.54M	$ -84.47M	$ -932.00K
Net Non Operating Interest Income Expense	-	-	$ -8.13M	-	-
Other Income Expense	$ -3.48M	$ -6.38M	$ -1.90M	$ -81.38M	$ -611.00K
Pretax Income	$ -163.66M	$ -171.41M	$ -122.77M	$ -165.85M	$ -1.54M
Tax Provision	$ -310.00K	$ -279.00K	$ -948.00K	$ -486.00K	$ 1.87M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -155.75M	$ -198.13M	$ -284.03M	$ -184.12M	$ -5.05M
Basic EPS	$ -1.70	$ -2.18	$ -4.19	$ -2.55	$ -0.07
Diluted EPS	$ -1.70	$ -2.18	$ -4.19	$ -2.55	$ -0.07
Basic Average Shares	$ 273.41M	$ 90.97M	$ 33.89M	$ 64.90M	$ 71.80M
Diluted Average Shares	$ 273.41M	$ 90.97M	$ 33.89M	$ 64.90M	$ 71.80M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 159.53M	$ 204.79M	$ -116.54M	$ 84.47M	$ 6.14M
Net Income From Continuing And Discontinued Operation	$ -155.75M	$ -198.13M	$ -121.82M	$ -165.37M	$ -3.41M
Normalized Income	$ -100.18M	$ -171.69M	-	$ -164.98M	$ -11.34M
Interest Expense	-	-	-	-	-
EBIT	$ -163.66M	$ -171.41M	$ -122.77M	$ -84.47M	$ -932.00K
EBITDA	$ -153.42M	$ -157.38M	$ -111.00M	$ -83.91M	$ -889.00K

Currency in USD

Prime Medicine, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing